Ara
Toplam kayıt 36, listelenen: 11-20
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
(Lippincott Williams & Wilkins, 2023)
Background:Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may ...
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM)
(Wiley, 2023)
Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions ...
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
(Kare Publishing, 2023)
Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan (R) is used for follow-up of fibrosis and steatosis. This single -cen-ter ...
The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients
(Kare Publishing, 2023)
Background and Aim: This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2.Materials ...
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply
(Wiley, 2023)
We appreciate the editorial comments by Drs. Sun and Fan about our study assessing the associations of patient-reported outcomes (PROs) and non-invasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) ...
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
(Elsevier, 2022)
Background & Aims: Non-invasive tests (NITs) offer a practical solution for advanced fibrosis identification in non-alcoholic
fatty liver disease (NAFLD). Despite increasing implementation, their use is not standardised, ...
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
(Kare Publishing, 2023)
Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
(Wolters Kluwer Medknow Publications, 2023)
Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective
treatment for NASH. This randomized, multicenter, double-blind, phase 2b
study ...
The heated debate over NAFLD renaming: An ongoing saga
(Kare Publishing, 2023)
In 1980, Jurgen Ludwig, a pathologist at the Mayo Clinic, and colleagues formally described a disorder that involved the accumulation
of fat in the liver, independent of significant alcohol consumption, or
other secondary ...
Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease
(Elsevier, 2023)
he study by Pischke et al. [1], which explores the relationships
between non-alcoholic steatohepatitis (NASH) and periodontitis, warrants commendation. The analysis involved 32 patients with NASH and
100 randomly, ...